Krsnaa Diagnost.

Why is Krsnaa Diagnostics Ltd falling/rising?

As of 06-Aug, Krsnaa Diagnostics Ltd's stock price is declining at 558.90, down 0.13%. This decline is driven by long-term underperformance, reduced investor participation, and weak financial growth prospects.

As of 06-Aug, Krsnaa Diagnostics Ltd is experiencing a slight decline in its stock price, currently at 558.90, reflecting a change of -0.75 (-0.13%). This decrease can be attributed to several factors highlighted in the provided data.<BR><BR>Despite a positive performance over the past week, where the stock rose by 6.72% compared to the Sensex's 1.32%, the overall year-to-date performance shows a significant decline of -22.41%, which is substantially worse than the Sensex's -7.35%. Additionally, the stock has underperformed over the past year, with a return of -33.19% compared to the Sensex's -1.97%. This long-term underperformance is a critical factor contributing to the current stock price decline.<BR><BR>Investor participation has also fallen, with delivery volume on 05 Aug decreasing by 28.04% against the 5-day average, indicating reduced interest from retail investors. Although there has been an increase in institutional investor participation, with a 1% rise in their stake over the previous quarter, the overall sentiment remains cautious due to the company's poor long-term growth metrics. The net sales growth of 14.13% and operating profit growth of 7.75% over the last five years are considered inadequate, leading to concerns about the company's future performance.<BR><BR>Furthermore, the company's financials reveal a low operating profit to interest ratio, which is the lowest at 4.54 times, and a decline in profit before tax (PBT) of -11.2% compared to the previous four-quarter average. These indicators suggest that the company is facing challenges that may deter investors, contributing to the stock's current downward trend. <BR><BR>In summary, the combination of long-term underperformance, declining investor participation, and lackluster financial growth prospects are key reasons for the falling stock price of Krsnaa Diagnostics Ltd.

Which are the latest news on Krsnaa Diagnost.?

What does Krsnaa Diagnost. do?

Krsnaa Diagnostics Ltd is a small-cap healthcare services company that provides diagnostic services. As of March 2026, it reported net sales of ₹193 Cr and a net profit of ₹42 Cr, with a market cap of ₹1,782 Cr.

Overview:<BR>Krsnaa Diagnostics Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History:<BR>The company was originally incorporated as Krsna Diagnostics Private Limited in 2010. It underwent a name change to Krsnaa Diagnostics Private Limited in 2015 and later converted to a public company, adopting the name Krsnaa Diagnostics Limited in May 2021. The latest quarterly results report net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 193 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 42 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 1,782 Cr (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: 17.00<BR>- Industry P/E: 60<BR>- Dividend Yield: 0.51%<BR>- Debt Equity: 0.18<BR>- Return on Equity: 10.35%<BR>- Price to Book: 1.79<BR><BR>Contact Details:<BR>- Address: S.No. 243/A Hissa No.6 Near, Chinchwad Station Chinchwad Pune Maharashtra : 411019<BR>- Tel: 91-20-46954695<BR>- Email: cs@krsnadiagnostics.com<BR>- Website: http://www.krsnaadiagnostics.com

How big is Krsnaa Diagnost.?

As of 10th June, Krsnaa Diagnostics Ltd has a market capitalization of 1,782.00 Cr, with recent net sales of 772.77 Cr and a net profit of 101.44 Cr. Shareholder's funds are 882.77 Cr, and total assets amount to 1,278.26 Cr.

As of 10th June, Krsnaa Diagnostics Ltd has a market capitalization of 1,782.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest four quarters, Krsnaa Diagnostics reported Net Sales of 772.77 Cr and a Net Profit of 101.44 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 882.77 Cr and Total Assets of 1,278.26 Cr.

Who are in the management team of Krsnaa Diagnost.?

The management team of Krsnaa Diagnost includes Rajendra Mutha (Executive Chairman), Pallavi Bhatevara (Managing Director), Yash Mutha (Whole-Time Director), and several independent directors, along with a Company Secretary. They oversee the company's operations and strategic direction.

The management team of Krsnaa Diagnost includes the following members:<BR><BR>1. **Rajendra Mutha** - Executive Chairman & Whole-Time Director<BR>2. **Pallavi Bhatevara** - Managing Director<BR>3. **Yash Mutha** - Whole-Time Director<BR>4. **Chetan Desai** - Independent Director<BR>5. **Chhaya Palrecha** - Independent Director<BR>6. **Rajiva Ranjan Verma** - Independent Director<BR>7. **Adesh Gupta** - Independent Director<BR>8. **Prem Pradeep** - Nominee<BR>9. **Sujoy Sudipta Bose** - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

Who are the peers of the Krsnaa Diagnost.?

Krsnaa Diagnost.'s peers include Metropolis Health, Thyrocare Tech, Suven Life Sciences, Vimta Labs, Suraksha Diagnostics, Laxmi Dental, One Global Services, and Tarsons Products. Krsnaa has average management risk, below-average growth, and a 1-year return of -21.61%.

Peers: The peers of Krsnaa Diagnost. are Metropolis Healt, Thyrocare Tech., Suven Life Scie., Vimta Labs, Suraksha Diagno., Laxmi Dental, One Global Serv, and Tarsons Products.<BR><BR>Quality Snapshot: Excellent management risk is observed at Metropolis Healt and Thyrocare Tech., while Average management risk is found at Vimta Labs, Krsnaa Diagnost., Laxmi Dental, One Global Serv, and the rest. Good management risk is seen at Suraksha Diagno., while Below Average management risk is noted for Suven Life Scie. and Tarsons Products. Growth is Good at Suraksha Diagno. and Laxmi Dental, while Below Average growth is present at Metropolis Healt, Thyrocare Tech., Suven Life Scie., Krsnaa Diagnost., Vimta Labs, and the rest. Excellent capital structure is noted for Metropolis Healt, Thyrocare Tech., Vimta Labs, Krsnaa Diagnost., One Global Serv, and the rest, while Good capital structure is seen at Suraksha Diagno., and Below Average capital structure is present at Suven Life Scie. and Tarsons Products.<BR><BR>Return Snapshot: The peer with the highest 1-year return is One Global Serv at 105.74%, while the lowest is Laxmi Dental at -48.44%. Krsnaa Diagnost.'s 1-year return is -21.61%, which is significantly lower than the highest and higher than the lowest. Additionally, the six-month return is negative for Vimta Labs, Suraksha Diagno., Laxmi Dental, Tarsons Products, and Krsnaa Diagnost.

Should I buy, sell or hold Krsnaa Diagnostics Ltd?

Are Krsnaa Diagnostics Ltd latest results good or bad?

Krsnaa Diagnostics Ltd's latest results show strong profit growth, with a net profit increase of 173.57% quarter-on-quarter, largely due to exceptional other income. However, modest revenue growth and reliance on one-time gains raise concerns about the sustainability of this performance.

Krsnaa Diagnostics Ltd's latest results present a mixed picture. On one hand, the company reported a significant increase in net profit for Q4 FY26, reaching ₹41.72 crores, which is a remarkable 173.57% increase quarter-on-quarter and a 101.74% increase year-on-year. The profit margin also improved substantially, with a PAT margin of 21.66%, up from 8.42% in the previous quarter.<BR><BR>However, this surge in profitability was largely driven by exceptional other income of ₹31.50 crores, which accounted for a significant portion of the profit. Without this one-time windfall, the net profit would have been much lower, around ₹18-20 crores, indicating that the underlying operational performance may not be as strong as the headline figures suggest.<BR><BR>The company's revenue growth was modest, with a 6.29% increase from the previous quarter and only 3.50% year-on-year growth. While the operating margin (excluding other income) improved to 28.49%, this reflects only incremental gains in operational efficiency.<BR><BR>Overall, while the quarterly results show impressive profit growth, the reliance on exceptional income raises concerns about sustainability and the true health of the core business. Investors should approach these results with caution, considering both the strong profit figures and the underlying operational challenges.

When is the next results date for Krsnaa Diagnostics Ltd?

The next results date for Krsnaa Diagnostics Ltd is 25 May 2026.

The next results date for Krsnaa Diagnostics Ltd is scheduled for 25 May 2026.

Is Krsnaa Diagnost. technically bullish or bearish?

As of December 3, 2025, Krsnaa Diagnostics shows a mildly bearish trend due to bearish MACD readings and Bollinger Bands, despite a mildly bullish daily moving average, and has underperformed compared to the Sensex.

As of 3 December 2025, the technical trend for Krsnaa Diagnostics has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD readings indicating a bearish trend, along with Bollinger Bands and KST also reflecting bearish signals. The moving averages on the daily timeframe show a mildly bullish stance, but this is overshadowed by the overall bearish indicators on the weekly and monthly timeframes. The stock has underperformed significantly compared to the Sensex over various periods, further supporting the bearish outlook.

How has been the historical performance of Krsnaa Diagnost.?

Krsnaa Diagnost. has shown consistent growth in net sales and profitability over the past four years, with net sales increasing from 455.45 Cr in Mar'22 to 717.16 Cr in Mar'25, and profit after tax rising from 68.39 Cr to 77.61 Cr in the same period. The company also improved its operating profit margin and cash flow from operating activities significantly.

Answer:<BR>The historical performance of Krsnaa Diagnost. shows a consistent growth trend in net sales and profitability over the past four years.<BR><BR>Breakdown:<BR>Krsnaa Diagnost. has demonstrated a steady increase in net sales, rising from 455.45 Cr in Mar'22 to 717.16 Cr in Mar'25. Total operating income followed a similar trajectory, reaching 717.16 Cr in Mar'25, up from 455.45 Cr in Mar'22. The company's total expenditure also increased, from 323.97 Cr in Mar'22 to 527.04 Cr in Mar'25, driven by higher raw material and employee costs. Operating profit (PBDIT) grew significantly, from 146.39 Cr in Mar'22 to 215.66 Cr in Mar'25, reflecting an improved operating profit margin of 26.51% in Mar'25 compared to 28.87% in Mar'22. Profit before tax increased from 86.51 Cr in Mar'22 to 102.69 Cr in Mar'25, while profit after tax rose from 68.39 Cr to 77.61 Cr in the same period. The company's total assets increased from 875.37 Cr in Mar'22 to 1,278.26 Cr in Mar'25, with total liabilities also rising from 875.37 Cr to 1,278.26 Cr. Cash flow from operating activities improved to 87.00 Cr in Mar'25, up from 24.00 Cr in Mar'24, indicating a positive cash flow trend. Overall, Krsnaa Diagnost. has shown robust growth in sales, profits, and asset base over the years.

Is Krsnaa Diagnost. overvalued or undervalued?

As of November 17, 2025, Krsnaa Diagnostics is fairly valued with a PE ratio of 31.76, lower than peers like Apollo Hospitals and Max Healthcare, and has outperformed the Sensex over the past three years with a return of 79.08%.

As of 17 November 2025, Krsnaa Diagnostics has moved from a very attractive to an attractive valuation grade. The company is currently considered fairly valued. Key ratios include a PE ratio of 31.76, an EV to EBITDA of 13.62, and a PEG ratio of 1.47. <BR><BR>In comparison to peers, Krsnaa Diagnostics has a lower PE ratio than Apollo Hospitals, which stands at 64.41, indicating that Krsnaa may be more reasonably priced despite its attractive valuation. Other peers like Max Healthcare and Fortis Healthcare are significantly more expensive, with PE ratios of 77.22 and 70.78, respectively. Although Krsnaa Diagnostics has underperformed the Sensex year-to-date, it has shown strong returns over the past three years, outperforming the index with a return of 79.08%.

Who are the top shareholders of the Krsnaa Diagnost.?

The top shareholders of Krsnaa Diagnost include Rajendra Khivraj Mutha with 24.87%, Phi Capital Trust - Phi Capital Growth Fund - I at 15.44%, individual investors with 29.13%, mutual funds holding 9.36%, and foreign institutional investors at 3.55%.

The top shareholders of Krsnaa Diagnost include Rajendra Khivraj Mutha, who holds the highest promoter stake at 24.87%. The highest public shareholder is Phi Capital Trust - Phi Capital Growth Fund - I, with a holding of 15.44%. Additionally, individual investors collectively hold 29.13% of the shares. The company also has mutual funds holding 9.36% across four schemes and foreign institutional investors (FIIs) holding 3.55% through 47 different entities.

Has Krsnaa Diagnost. declared dividend?

Krsnaa Diagnostics Ltd has declared a 50% dividend, amounting to ₹2.5 per share, with an ex-date of September 13, 2024. The company's total returns have varied significantly across different periods, with recent performance showing a total return of -30.77% over the last 6 months and 22.43% over the past year.

Krsnaa Diagnostics Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 2.5<BR>- Ex-date: Sep-13-2024<BR><BR>Dividend Yield: 0.38%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, Krsnaa Diagnostics experienced a price return of -30.77%, a dividend return of 0%, resulting in a total return of -30.77%.<BR><BR>Over the past year, the company saw a price return of 22.01% and a dividend return of 0.42%, leading to a total return of 22.43%.<BR><BR>In the 2-year period, the price return was 20.56%, with a dividend return of 0.90%, culminating in a total return of 21.46%.<BR><BR>For the 3-year period, Krsnaa Diagnostics had a price return of 21.22% and a dividend return of 1.52%, resulting in a total return of 22.74%.<BR><BR>In the 4-year period, the company recorded a price return of 0% and a dividend return of 0%, leading to a total return of 0.0%.<BR><BR>Over the last 5 years, Krsnaa Diagnostics experienced a price return of 0% and a dividend return of 0%, resulting in a total return of 0.0%.<BR><BR>Overall, Krsnaa Diagnostics has declared a dividend, but the total returns over various periods show significant variability, with some periods reflecting strong price returns while others indicate no dividend returns.